CN107735390B - 茚满胺衍生物的制备方法和新合成中间体 - Google Patents
茚满胺衍生物的制备方法和新合成中间体 Download PDFInfo
- Publication number
- CN107735390B CN107735390B CN201680006355.9A CN201680006355A CN107735390B CN 107735390 B CN107735390 B CN 107735390B CN 201680006355 A CN201680006355 A CN 201680006355A CN 107735390 B CN107735390 B CN 107735390B
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- group
- reaction
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000000543 intermediate Substances 0.000 title abstract description 18
- XJEVHMGJSYVQBQ-UHFFFAOYSA-N 2,3-dihydro-1h-inden-1-amine Chemical class C1=CC=C2C(N)CCC2=C1 XJEVHMGJSYVQBQ-UHFFFAOYSA-N 0.000 title description 5
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 claims abstract description 9
- 229960004078 indacaterol Drugs 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 86
- 238000006243 chemical reaction Methods 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 13
- 238000005727 Friedel-Crafts reaction Methods 0.000 claims description 12
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- -1 p-tosylate Chemical compound 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 7
- 238000005984 hydrogenation reaction Methods 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 125000006239 protecting group Chemical group 0.000 claims description 6
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 5
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 150000004820 halides Chemical class 0.000 claims description 3
- 238000005580 one pot reaction Methods 0.000 claims description 3
- 239000007858 starting material Substances 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical group CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 3
- 239000012320 chlorinating reagent Substances 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 8
- 238000003786 synthesis reaction Methods 0.000 abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- KKSIAGGARIMURJ-UHFFFAOYSA-N 4,5-diethyl-1H-inden-2-amine Chemical class C(C)C1=C2C=C(CC2=CC=C1CC)N KKSIAGGARIMURJ-UHFFFAOYSA-N 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropyl acetate Chemical compound CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 5
- KVNYFPKFSJIPBJ-UHFFFAOYSA-N 1,2-diethylbenzene Chemical compound CCC1=CC=CC=C1CC KVNYFPKFSJIPBJ-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 4
- YIAPLDFPUUJILH-UHFFFAOYSA-N indan-1-ol Chemical compound C1=CC=C2C(O)CCC2=C1 YIAPLDFPUUJILH-UHFFFAOYSA-N 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000002841 Lewis acid Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium chloride Substances Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 150000007517 lewis acids Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- IYOKXRGBXLKHGO-UHFFFAOYSA-N 1-(1-hydroxy-2,3-dihydroinden-1-yl)ethanone Chemical compound C1=CC=C2C(C(=O)C)(O)CCC2=C1 IYOKXRGBXLKHGO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001266 acyl halides Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical group OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical group CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000002050 international nonproprietary name Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/04—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups
- C07C209/22—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of other functional groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/04—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups
- C07C209/14—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of hydroxy groups or of etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
- C07C303/28—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
- C07C309/66—Methanesulfonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C35/22—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
- C07C35/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with hydroxy on a condensed ring system having two rings
- C07C35/32—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with hydroxy on a condensed ring system having two rings the condensed ring system being a (4.3.0) system, e.g. indenols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/18—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C43/188—Unsaturated ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
- C07C45/46—Friedel-Crafts reactions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/12—Acetic acid esters
- C07C69/14—Acetic acid esters of monohydroxylic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/12—Acetic acid esters
- C07C69/14—Acetic acid esters of monohydroxylic compounds
- C07C69/145—Acetic acid esters of monohydroxylic compounds of unsaturated alcohols
- C07C69/157—Acetic acid esters of monohydroxylic compounds of unsaturated alcohols containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/78—Benzoic acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明的主题为茚达特罗合成中的关键中间体的制备方法。本发明的主题还为新合成中间体。式(I):
Description
发明摘要
本发明的主题为茚达特罗合成中的关键中间体的制备方法。本发明的主题还为新合成中间体。
技术领域
茚达特罗是化合物(R)-5-[2-[(5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基]-1-羟乙基]-8-羟基喹啉-2(1H)-酮的国际非专有名,其具有下式:
茚达特罗是作为β-2受体选择性激动剂发挥作用的药物,其被推荐用于支气管痉挛和其他支气管病理状况,例如,支气管哮喘和慢性阻塞性肺疾病。
已知一些茚达特罗的合成方法,其使用具有下式的4,5-二乙基-1H-茚-2-基-胺
或其N-取代的衍生物(特别是N-苄基衍生物)作为关键中间体。所述中间体通常是从保护胺基团后的茚满胺(indanamine)开始来制备。例如,WO03/076387记载了从用三氟乙酰基保护的茚满胺开始,通过两个连续的弗里德-克拉夫茨反应(在各反应后还原所引入的酮基)来制备4,5-二乙基-1H-茚-2-基-胺。上述方法有以下缺点:需要将在各单独反应步骤后获得的化合物进行分离和纯化,由此导致与数次中间体分离相关的方法复杂性,并显然地导致收率损失。
此外记载其中R是苄基的衍生物的制备,其由4,5-二乙基-1H-茚-2-基-胺开始,根据以下路线将其胺基团与氯化苄反应,然后进行还原:
可以注意到,上面报道的苄基衍生物的制备需要两个额外的反应步骤,其影响合成的经济性,并决定了更高的成本,特别是在工业化生产的情况下。
WO00/75114记载了从二乙苯开始制备4,5-二乙基-1H-茚-2-基-胺;该方法导致非常低的收率,此外起始化合物(二乙苯)特别昂贵。这些缺点使得WO00/75114中记载的方法不是工业上关注的。
因此,存在对于发现简单实现且不需要中间体的复杂分离和纯化步骤的式(I)的化合物的合成方法的需求。
发明目的
本发明的目的是提供制备4,5-二乙基-1H-茚-2-基-胺或其N-衍生物的方法,其提供优异的收率和纯度,而不必定需要所有中间体化合物的分离和纯化。
本发明的另一目的是提供新的通用中间体衍生物,其可用于制备4,5-二乙基-1H-茚-2-基-胺或其N-衍生物,或作为其他化合物合成中的中间体。
发明描述
已发现可通过从茚满醇(indanol)开始的简单合成来制备4,5-二乙基-1H-茚-2-基-胺或其N-衍生物或者其盐。
因此,根据其一个方面,本发明的主题是制备式(I)的化合物或其盐的方法,
其中R是氢原子或者胺的保护基或活化基团,所述方法包括根据以下路线(I)的从(a)至(g)的下列步骤:
路线(I)
其中R如上所定义,Pr是不可通过氢化裂解的氧的保护基,并且X是亲核取代的离去基团。
具体地,本发明的主题是制备式(I)的化合物或其盐的方法,
其中R是氢原子或者胺的保护基或活化基团,所述方法包括:
(a)保护式(II)的化合物的羟基以得到式(III)的化合物;
(b)对所述式(III)的化合物进行弗里德-克拉夫茨反应以得到式(IV)的化合物;
(c)还原所述式(IV)的化合物以得到式(V)的化合物;
(d)对所述式(V)的化合物进行弗里德-克拉夫茨反应以得到式(VI)的化合物;
(e)还原所述式(VI)的化合物以得到式(VII)的化合物;
(f)将所述式(VII)的化合物的羟基脱保护以得到式(VIII)的化合物;
(g)引入X离去基团代替羟基以得到式(IX)的化合物;
(h)将所述式(XI)的化合物与式R-NH2的化合物反应以得到所述式(I)的化合物,并任选地将其转化为其盐。
本文中的“不可通过氢化裂解的氧的保护基”表示不会通过弗里德-克拉夫茨反应引入的第一个酮基团的还原反应而移除的保护基。这样的保护基包括乙酰基、三氟乙酰基和苯甲酰基以及具有对于弗里德-克拉夫茨反应无活性取代基的取代的苯甲酰基。
根据本发明优选的保护基是乙酰基。
本文中的“亲核取代的X离去基团”表示使化合物(VIII)上的亲核取代能够进行的基团。这样的基团包括甲磺酸酯、对甲苯磺酸酯、苯磺酸酯、三氟甲磺酸酯和卤素(例如氯和溴)。根据本发明优选的X基团是甲磺酸酯基团(也称为甲基磺酸酯基团)。
“胺的保护基或活化基团”包括苄基和取代的苄基,后者例如被给电子基团取代,未取代的苄基为优选基团。
在步骤(a)中,可根据本领域技术人员已知的技术进行羟基保护,有利地用酰卤,例如乙酰氯,其不昂贵且易于移除。此外,使用乙酰氯避免了式(III)的化合物的分离,并使步骤(a)和步骤(b)(即弗里德-克拉夫茨反应)能够以一锅反应的形式进行,因此无需分离中间体化合物。
步骤(b)的弗里德-克拉夫茨反应在酰卤存在下进行,有利地在酰氯和路易斯酸(例如根据已知技术的AlCl3)存在下进行。优选地,乙酰基-茚满醇/酰卤/路易斯酸的摩尔比率是约1/2-4/1.5-3.5,更优选是1/3/2.5。反应温度为-15℃至+10℃,有利地为-10℃至+0℃,例如约-10℃。
当步骤(a)和(b)的反应以一锅反应的形式进行时,乙酰基-茚满醇/酰卤/路易斯酸的摩尔比率优选是1/4/2.5。
步骤(b)中反应体积的稀释可从相对于起始产品的4-11体积变化,优选4-6体积的溶剂。出乎预料地注意到通过在低温下进行反应(例如低于0℃,有利地低于-5℃,例如约-10℃),并且通过降低所使用溶剂的量,可使不期望的异构体(即其中通过弗里德-克拉夫茨反应在3和6位引入基团的化合物)的形成减半。事实上,已观察到相对于通过使用更大溶剂体积获得的产物,4-6体积(相对于起始化合物)的稀释能够获得期望化合物收率的改善。可容易理解,除了显著增加反应收率外,这还涉及减少溶剂的使用,这从工业角度看,通过降低原料和处理的成本导致显著节省。该结果是独特和预料不到的。
可根据任何可能的已知技术进行步骤(c)的还原反应,例如酮在合适的溶剂中的催化氢化,例如在醇或乙酸中(例如在乙醇中),任选地加入乙酸,并且通过使用Pd/C作为催化剂。步骤(c)的优选的氢化的实例在下文的实验部分中提供。
在步骤(d)中,重复步骤(b)的弗里德-克拉夫茨反应以引入第二个取代基,其优选在上述条件下进行。
除非需要,不必分离式(VI)的中间体,并且随后的步骤(e)的还原反应(有利地根据步骤(c)所述的操作进行)可对步骤(d)的反应的粗产物进行。
也可不分离化合物(VII),并且步骤(f)的脱保护反应可对反应的粗产物根据本领域已知的任意方法进行,例如在诸如醇的溶剂中,于弱碱性环境中。例如,反应可通过在碱金属碳酸盐存在下,在乙醇中加热步骤(e)的反应的粗产物的混合物进行。
作为步骤(f)的其他选择,可在酸性pH下(例如在乙酸存在下),于约60-70℃的温度下进行氢化步骤(e)。在这种情况中,式(VI)的化合物被还原并同时被脱保护,直接得到式(VIII)的化合物。
从在上述条件下步骤(e)的反应或从步骤(f)(当进行时)得到的化合物(VIII)可不进行分离和纯化,并可直接对反应的粗产物进行步骤(g)的反应。
可根据本领域已知的方法进行步骤(g),例如由化合物(VIII)在合适的溶剂中的混合物,在碱性环境中(例如通过加入胺(如二异丙基乙胺)),并通过加入用于得到X基团的期望的试剂进行。例如,如果期望得到其中X是甲磺酸酯、对甲苯磺酸酯、苯磺酸酯、三氟甲磺酸酯基团等的化合物(VIII),可使用甲磺酰基卤化物、对甲苯磺酰基卤化物、苯磺酰基卤化物或三氟甲磺酰基卤化物,所述卤化物优选为氯化物。
作为另外的选择,如果期望得到其中X是卤素原子的化合物(VIII),可使用常规卤化剂,包括HX;因此,在氯的情况下,可使用常规氯化剂,例如HCl、SOCl2、PCl3、PCl5等。
根据优选的实施方案,X选自甲磺酸酯和对甲苯磺酸酯,有利地为甲磺酸酯。
式(IX)的化合物优选根据已知方法分离和纯化,并且通过在步骤(h)中与期望的式NH2R的胺反应转化为式(I)的化合物。当反应与氨或苄胺进行时,优选在无任何溶剂下,通过简单地加热式(IX)和胺的化合物的混合物进行。
根据优选的实施方案,本发明的方法根据以下路线(II)进行:
路线(II)
其中
Ac=乙酰基,Ms=甲磺酰基并且Bn=苄基。
根据特别优选的实施方案,根据以下路线(III),通过将步骤(a')和(b')合并在一起,并通过在酸性环境下且在约60-70℃的温度下进行步骤(e')的反应以避免步骤(f')来实施路线(II)的方法:
路线(III)
相对于已知合成(例如WO03/076387中记载的合成),本发明的方法能够以原创且甚至更简单的方式,通过使用特定顺序(如果上述反应涉及便宜的试剂,且不需要单独中间体的分离和纯化)来得到式(I)的化合物。事实上,在进行WO03/076387中所述的方法中,需要分离和结晶由各个步骤获得的几乎所有中间体,而在本发明的合成主题中,仅需要分离化合物(IV)和(IX)(参见路线(I))。这些进一步的处理显著地影响收率和工业成本,并且也由于这些原因,本发明的方法相对于已知技术为技术进步。
然而,如果需要,显然可将这样的中间体分离和纯化。
式(VII)、(VIII)、(IX)、(X)和(XI)的化合物(其中Ac是乙酰基)是新的且代表本发明的另一主题:
根据优选的实施方案,在式(IX)的化合物中,X选自卤素原子、甲磺酸酯基团、对甲苯磺酸酯基团、苯磺酸酯基团和三氟甲磺酸酯基团。
根据特别优选的实施方案,X选自氯原子、甲磺酸酯基团、对甲苯磺酸酯基团、苯磺酸酯基团和三氟甲磺酸酯基团。
特别优选的式(IX)的化合物是其中X为甲磺酸酯基团的化合物。
根据其另一方面,本发明的主题是制备式(VIII)的化合物的方法,其包括进行如上所定义的步骤(a)至(f)的反应。
根据其另一方面,本发明的主题是制备式(IX)的化合物的方法,其包括进行如上所定义的步骤(a)至(g)的反应。
如果需要,可根据本领域已知的方法将式(I)的化合物转化为其盐,例如转化为盐酸盐。
本发明的另一主题是通过本文中所述的方法获得的式(I)的化合物或其盐的用途,且请求保护其用于制备茚达特罗的用途。
本发明的主题还为至少一种选自如上所定义的式(VII)、(VIII)、(IX)、(X)和(XI)的化合物用于制备茚达特罗的用途。
本发明的另一主题是制备如上所定义的式(I)的化合物或其盐的方法,其包括:
在式(VIII)的化合物的羟基上引入式Pr'的基团
以得到式(IX)的化合物
将所述式(IX)的化合物与式R-NH2(其中R如上所定义)的化合物反应,以得到式(I)的化合物,并任选地将其转化为其盐。
根据优选的实施方案,在上面的方法中,X选自甲磺酸酯、对甲苯磺酸酯、苯磺酸酯和三氟甲磺酸酯以及卤素原子,有利地是氯。
根据另一优选的实施方案,在上述方法中,R是氢或苄基。
实验部分
定义
UPLC/MS超高效液相色谱偶联质谱检测器
DIPEA二异丙基乙胺
DCM二氯甲烷
iPrOAc乙酸异丙酯
IPA异丙醇
CG气相色谱法
步骤(a)+(b)
将21.2ml(298.32mmol)AcCl装入烧瓶中,冷却至0℃,并在约10min内加入10g(74.58mmol)茚满醇。将浴移除,并搅拌1h。将24.8g(186.45mmol)AlCl3装入三颈烧瓶中,加入70ml DCM,然后于0℃下冷却。然后将茚满醇溶液滴加至AlCl3在DCM中的悬浮液中。将其搅拌45min。通过UPLC/MS进行控制。将反应物滴加至200ml水和35ml浓HCl中,同时保持温度低于25℃。将其搅拌45min。将相分离,将水相用100ml DCM萃取一次。将其用100ml水洗涤,用硫酸钠干燥并浓缩至小体积。用庚烷/iPrOAc:4/1(50ml)进行重结晶。
步骤(c)
将在前面反应中得到的50.3g(230.5mmol)反应的粗产物在522g乙醇中溶解,装入氢化器,加入5g Pd/C。在环境温度下使其达到25bar。进行氢化直至反应完全(GC控制),然后在纤维素上进行催化剂过滤。将其在真空下浓缩至小体积。
步骤(d)
将18.22g(133.6mmol)AlCl3装入烧瓶中,并加入55ml DCM。将其冷却至0℃,并滴加11.65ml(161mmol)AcCl,同时保持温度为0℃。将其搅拌15min,然后加入前面反应中得到的11g反应的粗产物(53.44mmol),同时保持温度为0℃。将其搅拌约1h,并检查UPLC/MS进展。将反应物滴加至160ml冷水和35ml浓HCl中,同时保持温度低于25℃,并搅拌45min。将相分离,将水相用80ml DCM萃取一次。将其用100ml水洗涤,用硫酸钠干燥并浓缩至小体积。
步骤(d)
将在前面反应中得到的12.4g(50.35mmol)反应的粗产物在350ml乙醇中溶解,装入氢化器,并加入1.33g Pd/C。使其达50℃和25bar,并进行氢化直至反应完全。
步骤(f)
将在前面反应中得到的10.4g(44.76mmol)反应的粗产物装入烧瓶中,并加入85ml甲醇和35ml水。加入12.4g(89.52mmol)K2CO3,并将其搅拌过夜。通过UPLC/MS检查反应完成。将其用35ml水稀释,用80ml DCM萃取2次,用硫酸钠干燥并浓缩至小体积。
步骤(g)
将3.508g(18.43mmol)底物装入烧瓶中,并加入30ml DCM。将其冷却至0℃,并滴加3.852ml(22.11mmol)DIPEA。滴加1.570ml(20.27mmol)MsCl,并将其搅拌直至反应完全(其通过UPLC检查)。将其用20ml 2M HCl洗涤,将相分离,将有机相用30ml NaHCO3洗涤,然后用30ml HCl洗涤。将其用硫酸钠干燥,并浓缩至小体积。用iPrOAc/庚烷1:10(35ml)进行结晶。收率:62%,白色固体。
步骤(h)
将2.285ml(20.9mmol)苄胺装入烧瓶中,将其加热至80℃。将在步骤(g)中得到的1.871g(6.97mmol)化合物分批加入,然后加热至80℃。通过UPLC/MS检查反应。用35ml DCM进行稀释,然后用15ml 5%柠檬酸洗涤以移除未反应的苄胺。将相分离,并将有机相用15ml1M NaOH洗涤。将其脱水并浓缩至小体积,用10ml丙酮洗涤,并滴加700μl浓HCl。用Buchner过滤器过滤沉淀物。得到1.7g白色固体(摩尔收率=80%)。可将产物结晶(例如在IPA中)以进一步纯化。所述产物包含少于0.7-0.2%(GC分析)的位置异构体。
从(a)至(h)的总收率为50%。
Claims (14)
1.制备式(I)的化合物或其盐的方法,
其中R是苄基,所述方法包括:
(a)保护式(II)的化合物的羟基
以得到式(III)的化合物
(b)对所述式(III)的化合物进行弗里德-克拉夫茨反应以得到式(IV)的化合物
(c)将所述式(IV)的化合物氢化以得到式(V)的化合物
(d)对所述式(V)的化合物进行弗里德-克拉夫茨反应以得到式(VI)的化合物
(e)将所述式(VI)的化合物氢化以得到式(VII)的化合物
(f)将所述式(VII)的化合物的羟基脱保护以得到式(VIII)的化合物
(g)引入式X的基团以得到式(IX)的化合物;
(h)将所述式(IX)的化合物与式R-NH2的化合物反应以得到所述式(I)的化合物,并任选地将其转化为其盐,
其中R如上所定义;Pr是不可通过氢化裂解的氧的保护基,其选自乙酰基、三氟乙酰基、苯甲酰基以及具有一个或多个对于弗里德-克拉夫茨反应无活性取代基的取代的苯甲酰基;并且X是选自甲磺酸酯、对甲苯磺酸酯、苯磺酸酯、三氟甲磺酸酯和卤素原子的亲核取代的离去基团。
2.根据权利要求1所述的方法,其特征在于Pr选自乙酰基、三氟乙酰基和苯甲酰基。
3.根据权利要求1或2所述的方法,其特征在于步骤(a)和(b)用酰卤进行,并以一锅反应进行。
4.根据权利要求1或2所述的方法,其特征在于步骤(c)和步骤(e)在溶剂和催化剂的存在下通过氢化进行。
5.根据权利要求1或2所述的方法,其特征在于不进行步骤(f),并且在步骤(e)中将酮还原,同时将所述羟基脱保护,以直接得到所述式(VIII)的化合物。
6.根据权利要求1或2所述的方法,其特征在于在步骤(g)中使用甲磺酰基卤化物或甲苯磺酰基卤化物,或者氯化剂。
7.根据权利要求1或2所述的方法,其特征在于步骤(b)和(d)在低于零的温度下进行,并用相对于起始化合物4-6体积的溶剂稀释。
9.通过权利要求1-7中任一项所述的方法得到的式(I)的化合物或其盐用于制备茚达特罗的用途。
12.根据权利要求11所述的方法,其特征在于所述卤素原子为氯原子。
13.制备式(IX)的化合物的方法,其包括进行如权利要求1-7中任一项所定义的步骤(a)至(g)的反应。
14.根据权利要求13所述的方法,其特征在于X是甲磺酸酯基团。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI20150045 | 2015-01-20 | ||
ITMI2015A000045 | 2015-01-20 | ||
PCT/IB2016/050249 WO2016116857A1 (en) | 2015-01-20 | 2016-01-19 | Process for the preparation of indanamine derivatives and new synthesis intermediates |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107735390A CN107735390A (zh) | 2018-02-23 |
CN107735390B true CN107735390B (zh) | 2021-06-08 |
Family
ID=52727243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680006355.9A Active CN107735390B (zh) | 2015-01-20 | 2016-01-19 | 茚满胺衍生物的制备方法和新合成中间体 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10059653B2 (zh) |
EP (1) | EP3247693B1 (zh) |
JP (1) | JP6637069B2 (zh) |
CN (1) | CN107735390B (zh) |
CA (1) | CA2973318A1 (zh) |
ES (1) | ES2758677T3 (zh) |
WO (1) | WO2016116857A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110183330B (zh) * | 2019-06-05 | 2022-05-27 | 安徽华邦药业有限公司 | 一种5,6-二乙基-2,3-二氢-1h-茚-2-胺盐酸盐的制备方法 |
CN114751857A (zh) * | 2022-04-29 | 2022-07-15 | 梯尔希(南京)药物研发有限公司 | 一种茚达特罗杂质的制备方法 |
CN116183758B (zh) * | 2023-01-16 | 2023-11-03 | 山东京卫制药有限公司 | 一种二乙基茚胺盐酸盐中异构体杂质的分析方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006128674A2 (en) * | 2005-05-31 | 2006-12-07 | Novartis Ag | Combinations of indacaterol derivatives and other agents for the treatment of airway diseases |
CN101273026A (zh) * | 2005-09-30 | 2008-09-24 | 霍夫曼-拉罗奇有限公司 | 作为mch受体拮抗剂的茚满衍生物 |
CN101379046A (zh) * | 2005-12-21 | 2009-03-04 | 挂毯药品公司 | 制备紫杉烷衍生物的方法以及用于其中的中间体 |
WO2013132514A2 (en) * | 2012-03-09 | 2013-09-12 | Rao Davuluri Ramamohan | A novel process for the preparation of (r)-5-[2-[(5, 6-diethyl-2, 3-dihydro-1h-inden-2-yl) amino]-1-hydroxyethyl]-8-hydroxy quinolin-2(1h)-one |
CN103360264A (zh) * | 2013-07-18 | 2013-10-23 | 武汉恒和达生物医药有限公司 | 茚达特罗氨基片段5,6-二乙基-2,3-二氢-1h-茚-2-胺盐酸盐的合成方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9913083D0 (en) * | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
US6933410B2 (en) | 2002-03-08 | 2005-08-23 | Novartis Ag | Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine |
-
2016
- 2016-01-19 CA CA2973318A patent/CA2973318A1/en not_active Abandoned
- 2016-01-19 EP EP16709126.3A patent/EP3247693B1/en active Active
- 2016-01-19 US US15/541,931 patent/US10059653B2/en active Active
- 2016-01-19 WO PCT/IB2016/050249 patent/WO2016116857A1/en active Application Filing
- 2016-01-19 CN CN201680006355.9A patent/CN107735390B/zh active Active
- 2016-01-19 ES ES16709126T patent/ES2758677T3/es active Active
- 2016-01-19 JP JP2017555864A patent/JP6637069B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006128674A2 (en) * | 2005-05-31 | 2006-12-07 | Novartis Ag | Combinations of indacaterol derivatives and other agents for the treatment of airway diseases |
CN101273026A (zh) * | 2005-09-30 | 2008-09-24 | 霍夫曼-拉罗奇有限公司 | 作为mch受体拮抗剂的茚满衍生物 |
CN101379046A (zh) * | 2005-12-21 | 2009-03-04 | 挂毯药品公司 | 制备紫杉烷衍生物的方法以及用于其中的中间体 |
WO2013132514A2 (en) * | 2012-03-09 | 2013-09-12 | Rao Davuluri Ramamohan | A novel process for the preparation of (r)-5-[2-[(5, 6-diethyl-2, 3-dihydro-1h-inden-2-yl) amino]-1-hydroxyethyl]-8-hydroxy quinolin-2(1h)-one |
CN103360264A (zh) * | 2013-07-18 | 2013-10-23 | 武汉恒和达生物医药有限公司 | 茚达特罗氨基片段5,6-二乙基-2,3-二氢-1h-茚-2-胺盐酸盐的合成方法 |
Non-Patent Citations (1)
Title |
---|
An Efficient and Economical Synthesis of 5,6-Diethyl-2,3-dihydro-1H-inden-2-amine Hydrochloride;Mahavir Prashad等;《Organic Process Research & Development》;20061231;第1卷(第10期);第135页左栏,第136页Scheme 2 * |
Also Published As
Publication number | Publication date |
---|---|
CA2973318A1 (en) | 2016-07-28 |
EP3247693B1 (en) | 2019-09-04 |
ES2758677T3 (es) | 2020-05-06 |
EP3247693A1 (en) | 2017-11-29 |
JP6637069B2 (ja) | 2020-01-29 |
CN107735390A (zh) | 2018-02-23 |
WO2016116857A1 (en) | 2016-07-28 |
US20170362161A1 (en) | 2017-12-21 |
US10059653B2 (en) | 2018-08-28 |
JP2018502164A (ja) | 2018-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107735390B (zh) | 茚满胺衍生物的制备方法和新合成中间体 | |
CA3077888C (en) | Indacaterol free base in solid form | |
JP2010518144A (ja) | Z異性体を実質的に含まないエンタカポンを製造する方法、その合成中間体、及び新規な結晶形態 | |
WO2008035381A2 (en) | Process for the preparation of amine derivatives as calcimimetics | |
JP2014509640A (ja) | N−ブチル化によるドロネダロンの調製方法 | |
EP3490973B1 (en) | Polymorphic forms of belinostat and processes for preparation thereof | |
US11465999B2 (en) | Process for preparing Alectinib or a pharmaceutically acceptable salt thereof | |
KR20120027015A (ko) | 6-(아릴)-4-아미노피콜리네이트의 제조 방법 | |
ITMI20100284A1 (it) | Nuovo procedimento per la preparazione del dronedarone | |
JP5696035B2 (ja) | アルガトロバン一水和物の多形体及びその合成方法 | |
JP2018536640A (ja) | イブルチニブ及びその中間体の製造方法 | |
KR100425232B1 (ko) | 로피바카인히드로클로라이드모노히드레이트의신규제조방법 | |
KR100772244B1 (ko) | 밀나시프란염산염의 제조방법 | |
EP3807268B1 (en) | Process for the preparation of lifitegrast | |
EP1791808B1 (en) | Process for the preparation of 4,5-diamino shikimicacid | |
GB2290790A (en) | Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes | |
EP4063351A1 (en) | Preparation method of quinoline derivative compounds | |
KR100469030B1 (ko) | 시사프라이드의 합성방법 | |
EP3356322B1 (en) | Process for the preparation of indanamine derivatives and new synthesis intermediates | |
Bridges | A Synthesis of the Potent A2 Selective Adenosine Agonist N6-[2-(3, 5-Dimethoxyphenyl)-2-(2-Methylphenyl) Ethyl] Adenosine, and Its 5′-N-Ethyl Ribofuranuronamide Derivative | |
KR100350507B1 (ko) | 시사프라이드 및 그 중간체의 제조방법 | |
EP3848354B1 (en) | Process for the preparation of indacaterol and intermediates thereof | |
JP2022529000A (ja) | 置換2-[2-(フェニル)エチルアミノ]アルカンアミド誘導体の製造方法 | |
EA026170B1 (ru) | Способ получения ивабрадина и промежуточных продуктов его синтеза | |
CN117551038A (zh) | 一种硼酸促进4-溴-7-甲基-1h-吲唑关环制备的合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |